- Home
- MIRM vs IFS Comparison
MIRM vs IFS Comparison
Compare MIRM & IFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- IFS
- Stock Information
- Founded
- MIRM 2018
- IFS 1897
- Country
- MIRM United States
- IFS Peru
- Employees
- MIRM 349
- IFS N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- IFS Commercial Banks
- Sector
- MIRM Health Care
- IFS Finance
- Exchange
- MIRM Nasdaq
- IFS Nasdaq
- Market Cap
- MIRM 3.7B
- IFS 4.2B
- IPO Year
- MIRM 2019
- IFS 2019
- Fundamental
- Price
- MIRM $72.85
- IFS $40.70
- Analyst Decision
- MIRM Strong Buy
- IFS
- Analyst Count
- MIRM 11
- IFS 0
- Target Price
- MIRM $76.09
- IFS N/A
- AVG Volume (30 Days)
- MIRM 712.9K
- IFS 217.1K
- Earning Date
- MIRM 11-11-2025
- IFS 11-11-2025
- Dividend Yield
- MIRM N/A
- IFS 2.36%
- EPS Growth
- MIRM N/A
- IFS 112.04
- EPS
- MIRM N/A
- IFS 4.72
- Revenue
- MIRM $429,161,000.00
- IFS $1,506,553,476.00
- Revenue This Year
- MIRM $53.14
- IFS N/A
- Revenue Next Year
- MIRM $19.83
- IFS $3.48
- P/E Ratio
- MIRM N/A
- IFS $8.37
- Revenue Growth
- MIRM 62.33
- IFS 39.88
- 52 Week Low
- MIRM $36.88
- IFS $25.77
- 52 Week High
- MIRM $78.10
- IFS $42.21
- Technical
- Relative Strength Index (RSI)
- MIRM 56.46
- IFS N/A
- Support Level
- MIRM $70.49
- IFS N/A
- Resistance Level
- MIRM $74.96
- IFS N/A
- Average True Range (ATR)
- MIRM 1.82
- IFS 0.00
- MACD
- MIRM -0.72
- IFS 0.00
- Stochastic Oscillator
- MIRM 51.03
- IFS 0.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About IFS Intercorp Financial Services Inc.
Intercorp Financial Services Inc is a provider of banking, insurance, wealth management services and payments for retail customers and commercial clients in Peru. The company has four operating segments; the Banking segment includes Mainly loans, credit facilities, deposits, and current accounts, the Insurance segment provides life annuity products with single-premium payment and conventional life insurance products and other retail insurance products, the Wealth Management segment provides brokerage and investment management services. Its geographical segments include Peru and Panama.